Walleye Capital
GTHX

Walleye Capital’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Walleye Capital’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-27,279
Closed -$300K – 1042
2020
Q1 		$300K Buy
+27,279
New +$509K 0.07% 342

Other funds holding GTHX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Walleye Capital's GTHX Position: Q2 2020 in Review

Walleye Capital sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2020, closing a stake of 27,279 shares — an estimated $300K sold.

Walleye Capital first reported a position in GTHX in Q1 2020 and held it in 1 quarter. The position peaked at $300K in Q1 2020. 100 funds tracked by Wall St. Rank hold GTHX as of Q2 2020.

  • Walleye Capital reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Walleye Capital sold 27,279 G1 Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $300K.
  • Walleye Capital first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2020 and held it in 1 quarter.
  • Walleye Capital's G1 Therapeutics, Inc. Common Stock position peaked at $300K in Q1 2020.
  • 100 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Walleye Capital's 13F filing for Q2 2020, filed 14 Aug 2020.